Literature DB >> 22787236

Early cytokine elevation, PrPres deposition, and gliosis in mouse scrapie: no effect on disease by deletion of cytokine genes IL-12p40 and IL-12p35.

Déborah Tribouillard-Tanvier1, Brent Race, James F Striebel, James A Carroll, Katie Phillips, Bruce Chesebro.   

Abstract

Neurodegenerative diseases are typically associated with an activation of glia and an increased level of cytokines. In our previous studies of prion disease, the cytokine response in the brains of clinically sick scrapie-infected mice was restricted to a small group of cytokines, of which IL-12p40, CCL2, and CXCL10 were present at the highest levels. The goal of our current research was to determine the relationship between cytokine responses, gliosis, and neuropathology during prion disease. Here, in time course studies of C57BL/10 mice intracerebrally inoculated with 22L scrapie, abnormal protease-resistant prion protein (PrPres), astrogliosis, and microgliosis were first detected at 40 days after intracerebral scrapie inoculation. In cytokine studies, IL-12p40 was first elevated by 60 days; CCL3, IL-1β, and CXCL1 were elevated by 80 days; and CCL2 and CCL5 were elevated by 115 days. IL-12p40 showed the most extensive increase throughout disease and was 30-fold above control levels at the terminal stage. Because of the early onset and dramatic elevation of IL-12p40 during scrapie, we investigated whether IL-12p40 contributed to the development of prion disease neuropathogenesis by using three different scrapie strains (22L, RML, 79A) to infect knockout mice in which the gene encoding IL-12p40 was deleted. We also studied knockout mice lacking IL-12p35, which combines with IL-12p40 to form active IL-12 heterodimers. In all instances, knockout mice did not differ from control mice in survival time, clinical tempo, or levels of spongiosis, gliosis, or PrPres in the brain. Thus, neither IL-12p40 nor IL-12p35 molecules were required for prion disease-associated neurodegeneration or neuroinflammation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22787236      PMCID: PMC3457249          DOI: 10.1128/JVI.01340-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Tumor necrosis factor alpha-deficient, but not interleukin-6-deficient, mice resist peripheral infection with scrapie.

Authors:  N A Mabbott; A Williams; C F Farquhar; M Pasparakis; G Kollias; M E Bruce
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Crucial role for prion protein membrane anchoring in the neuroinvasion and neural spread of prion infection.

Authors:  Mikael Klingeborn; Brent Race; Kimberly D Meade-White; Rebecca Rosenke; James F Striebel; Bruce Chesebro
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

3.  beta-adrenergic receptor stimulation selectively inhibits IL-12p40 release in microglia.

Authors:  M Prinz; K G Häusler; H Kettenmann; U Hanisch
Journal:  Brain Res       Date:  2001-04-27       Impact factor: 3.252

4.  Evaluation of prion deposits and microglial activation in scrapie-infected mice using molecular imaging probes.

Authors:  Pu-Jiao Song; Céline Barc; Nicolas Arlicot; Denis Guilloteau; Serge Bernard; Pierre Sarradin; Sylvie Chalon; Lucette Garreau; Hank F Kung; Frédéric Lantier; Jackie Vergote
Journal:  Mol Imaging Biol       Date:  2010-12       Impact factor: 3.488

5.  Role of cyclophilin A from brains of prion-infected mice in stimulation of cytokine release by microglia and astroglia in vitro.

Authors:  Déborah Tribouillard-Tanvier; James A Carroll; Roger A Moore; James F Striebel; Bruce Chesebro
Journal:  J Biol Chem       Date:  2011-12-16       Impact factor: 5.157

6.  Analysis of protein levels of 24 cytokines in scrapie agent-infected brain and glial cell cultures from mice differing in prion protein expression levels.

Authors:  Déborah Tribouillard-Tanvier; James F Striebel; Karin E Peterson; Bruce Chesebro
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

7.  Accelerated prion replication in, but prolonged survival times of, prion-infected CXCR3-/- mice.

Authors:  Constanze Riemer; Julia Schultz; Michael Burwinkel; Anja Schwarz; Simon W F Mok; Sandra Gültner; Theresa Bamme; Stephen Norley; Frank van Landeghem; Bao Lu; Craig Gerard; Michael Baier
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

8.  Investigation of mcp1 as a quantitative trait gene for prion disease incubation time in mouse.

Authors:  Marie O'Shea; Emma G Maytham; Jackie M Linehan; Sebastian Brandner; John Collinge; Sarah E Lloyd
Journal:  Genetics       Date:  2008-08-20       Impact factor: 4.562

9.  Limited transcriptional response of ovine microglia to prion accumulation.

Authors:  James B Stanton; Donald P Knowles; Douglas R Call; Bruce A Mathison; Timothy V Baszler
Journal:  Biochem Biophys Res Commun       Date:  2009-06-10       Impact factor: 3.575

10.  Strain specific resistance to murine scrapie associated with a naturally occurring human prion protein polymorphism at residue 171.

Authors:  James F Striebel; Brent Race; Kimberly D Meade-White; Rachel LaCasse; Bruce Chesebro
Journal:  PLoS Pathog       Date:  2011-09-29       Impact factor: 6.823

View more
  22 in total

1.  Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice.

Authors:  James A Carroll; Brent Race; Katie Phillips; James F Striebel; Bruce Chesebro
Journal:  J Gen Virol       Date:  2017-07-31       Impact factor: 3.891

2.  Increased infectivity of anchorless mouse scrapie prions in transgenic mice overexpressing human prion protein.

Authors:  Brent Race; Katie Phillips; Kimberly Meade-White; James Striebel; Bruce Chesebro
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

3.  LPS induces mediators of neuroinflammation, cell proliferation, and GFAP expression in human astrocytoma cells U373MG: the anti-inflammatory and anti-proliferative effect of guggulipid.

Authors:  Rituraj Niranjan; Rajasekar Nagarajan; Kashif Hanif; Chandishwar Nath; Rakesh Shukla
Journal:  Neurol Sci       Date:  2013-09-07       Impact factor: 3.307

4.  Celecoxib Inhibits Prion Protein 90-231-Mediated Pro-inflammatory Responses in Microglial Cells.

Authors:  Valentina Villa; Stefano Thellung; Alessandro Corsaro; Federica Novelli; Bruno Tasso; Luca Colucci-D'Amato; Elena Gatta; Michele Tonelli; Tullio Florio
Journal:  Mol Neurobiol       Date:  2014-11-18       Impact factor: 5.590

5.  Prion infection of mouse brain reveals multiple new upregulated genes involved in neuroinflammation or signal transduction.

Authors:  James A Carroll; James F Striebel; Brent Race; Katie Phillips; Bruce Chesebro
Journal:  J Virol       Date:  2014-12-10       Impact factor: 5.103

6.  Microglia Are Critical in Host Defense against Prion Disease.

Authors:  James A Carroll; Brent Race; Katie Williams; James Striebel; Bruce Chesebro
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

7.  Knockout of fractalkine receptor Cx3cr1 does not alter disease or microglial activation in prion-infected mice.

Authors:  James F Striebel; Brent Race; James A Carroll; Katie Phillips; Bruce Chesebro
Journal:  J Gen Virol       Date:  2016-03-02       Impact factor: 3.891

8.  Prion pathogenesis in the absence of NLRP3/ASC inflammasomes.

Authors:  Mario Nuvolone; Silvia Sorce; Petra Schwarz; Adriano Aguzzi
Journal:  PLoS One       Date:  2015-02-11       Impact factor: 3.240

9.  Early Generation of New PrPSc on Blood Vessels after Brain Microinjection of Scrapie in Mice.

Authors:  Bruce Chesebro; James Striebel; Alejandra Rangel; Katie Phillips; Andrew Hughson; Byron Caughey; Brent Race
Journal:  MBio       Date:  2015-09-22       Impact factor: 7.867

Review 10.  Prion disease and the innate immune system.

Authors:  Barry M Bradford; Neil A Mabbott
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.